3D Mesothelioma Spheroids Reveal Why Chemo Often Fails

A team of Australian researchers has built a three-dimensional model of pleural mesothelioma that reproduces how patient tumors resist standard chemotherapy, identifying signaling pathways that may explain why most patients eventually progress on the cisplatin and pemetrexed combination that has been the first-line standard of care for two decades.

The study, published in Scientific Reports in February, established that 3D spheroids of mesothelioma cells survive chemotherapy at higher doses than flat-dish 2D cultures of the same cells, with reduced apoptosis and altered cell-cycle profiles. The findings position the spheroid system as a more physiologically relevant platform for testing new mesothelioma drugs.

Why 2D Cultures Fall Short

Most preclinical cancer drug research uses 2D cell cultures grown on plastic dishes. Drugs are screened for activity, then advanced toward clinical trials based on those results. The model is fast and inexpensive, but it does not replicate the conditions inside an actual tumor, where cells form three-dimensional clusters with limited oxygen, restricted nutrient access, and complex interactions with surrounding tissue.

The translational gap shows up in clinical trial results. Many mesothelioma drug candidates that look promising in 2D screens fail to show meaningful benefit in patients. The Australian team set out to build a model that more closely matches the tumor microenvironment people with mesothelioma actually have.

What the 3D Model Showed

The researchers grew mesothelioma cells from multiple histological subtypes as 3D spheroids, then tested them against cisplatin combined with pemetrexed, the chemotherapy doublet that has been the standard first-line regimen since 2003. The 3D cultures required substantially higher drug concentrations to achieve the same cell-kill seen in 2D, with elevated IC₅₀ values across subtypes.

Apoptosis, the form of programmed cell death triggered by chemotherapy, was reduced in the spheroids. Cell-cycle profiling showed the 3D cultures shifted toward a slower-cycling state, consistent with quiescent tumor cells that evade drugs targeted at dividing cells.

Seahorse metabolic analysis, which measures real-time cellular energy production, found that the spheroids had suppressed oxidative phosphorylation, the mitochondrial pathway that normally generates most of a cell’s energy. Unexpectedly, the cells did not compensate by upregulating glycolysis, the alternative energy pathway many cancers use under stress. The combined pattern fits the hypoxic and nutrient-restricted conditions described in actual mesothelioma lesions.

The Signaling Pathways That Matter

Proteomic analysis of the 3D cultures identified two signaling networks that were upregulated in spheroids compared to 2D cells: PI3K/AKT and Notch/VEGF. Both pathways are known drivers of cancer cell survival and resistance to therapy in other tumor types.

PI3K/AKT signaling controls cell growth, survival, and metabolism. Drugs targeting this pathway are approved or in development for several cancers. Notch signaling regulates how cells differentiate and communicate, and Notch activation has been linked to chemotherapy resistance in lung and breast cancers. VEGF promotes blood vessel growth around tumors, supporting their nutrient supply.

The team also identified subtype-specific microRNA signatures in the spheroids that closely matched data from patient tumor samples, suggesting the 3D model preserves disease-relevant gene regulation that gets lost in 2D culture.

What This Means for Future Treatments

Histological assessment of mouse xenografts confirmed that the 3D spheroid model captured the fibrotic stroma, areas of necrosis, and treatment-response patterns seen in patient tumors. That validation supports using the model as a screening platform for new drugs and combination regimens.

For patients today, the findings do not change the standard of care. Cisplatin-pemetrexed remains the foundation of first-line chemotherapy, and recent approvals have added immunotherapy options including nivolumab plus ipilimumab and the pembrolizumab-chemotherapy combination. But the work helps explain why chemotherapy alone often fails to produce durable responses, and it points to PI3K/AKT and Notch as candidate pathways for future combination trials.

The research team draws from institutions in Sydney, including the Asbestos Diseases Research Institute, the University of Sydney, and the University of Technology Sydney, with collaborators from Flinders University and Western Sydney University. The paper is open access.